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Abstract
Background: Plants that are used as traditional medicine represent a relevant pool for selecting plant candidates
that may have anticancer properties. In this study, the ethnomedicinal approach was used to select several
medicinal plants native to Nigeria, on the basis of their local or traditional uses. The collected plants were then
evaluated for cytoxicity.
Methods: The antitumor activity of methanolic extracts obtained from 24 of the selected plants, were evaluated
in vitro on five human cancer cell lines.
Results: Results obtained from the plants screened indicate that 18 plant extracts of folk medicine exhibited
promising cytotoxic activity against human carcinoma cell lines. Erythrophleum suaveolens (Guill. & Perr.) Brenan was
found to demonstrate potent anti-cancer activity in this study exhibiting IC50 = 0.2-1.3 μg/ml.
Conclusions: Based on the significantly potent activity of some plants extracts reported here, further studies aimed
at mechanism elucidation and bio-guided isolation of active anticancer compounds is currently underway.
Keywords: Nigeria, Anti-cancer, Ethnomedicine, Cytotoxic activity
Background
Currently, one in four deaths in the United States is due
to cancer [1]. When ranked within age groups, cancer is
one of the five leading causes of death amongst both
males and females and the single largest cause of death
worldwide [1]. By 2015 cancer morbidity may climb to
around nine million world-wide. This growing trend in-
dicates deficiency in the present cancer therapies which
include surgical operation, radiotherapy and chemother-
apy. Since the average survival rates have remained es-
sentially unchanged despite such aggressive treatments,
there is a critical need for anti-cancer agents with higher
efficacy, and less side effects that can be acquired at an
affordable cost.
We suppose that plants are the best alternative, as they
provide an inexhaustible pool of efficacious agents for
treating disease. Phytochemicals have always been
sought after because of their inherent potential to cure
disease, as demonstrated by ancient medicinal practices
[2-5]. Furthermore, several plants have been shown to
be sources of therapeutically important agents, valuable
in the treatment of cancer. For instance, there are very
effective cancer chemotherapeutic drugs that have been
derived from natural origin [6]. These include plant-
derived agents, such as the vinca alkaloids vinblastine
and vincristine, isolated from the Madagascar periwinkle,
Catharanthus roseus (L.) G. Don. [7]; paclitaxel (Taxol),
originally isolated from the bark of the Pacific yew tree
from the Pacific Northwest, Taxus brevifolia Nutt., and
the analogue, docetaxel [8]; etoposide and teniposide,
derived semisynthetically from epipodophyllotoxin, an
epimer of podophyllotoxin, isolated from roots of Podo-
phyllum species [9]; and camptothecin, isolated from the
bark of Camptotheca acuminata Decne., a precursor to
the semisynthethetic drugs topotecan (Hycamptin) and
irinotecan (Camptosar) [10].
There are estimated to be between 200,000 and
450,000 species of tropical flowering plants within our
biosphere, with the greatest plant diversity being found
in the moist tropics [11,12]. The approaches for selecting
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plants to be tested for new bioactive compounds range
from random selection to ethnopharmalogical approa-
ches relying on knowledge gained from traditional medi-
cine usage. Traditional medicine occupies a central role
in the developing nations [13].
Although there have been vast discoveries of potent cyto-
toxic agents attributed to Asian and Ayurvedic Indian trad-
itional medicine, the need for this study is derived from the
fact that much of the medicinal plants found in Africa are
unexplored. Drug discovery of African plants is of relevant
interest because Africa hosts 57,704 species of the world’s
flora [14] and although Africans use over 5000 of their plants
for medicinal purposes, the study of African medicinal plants
has not been accredited or documented as extensively as the
Chinese and Indian herbal medicines [13,15]. The potential
of Nigerian flora in particular, as a veritable source for phar-
maceuticals and other therapeutic materials has been well
documented [16]. In the present study, we performed the
preliminary screening of 24 methanolic plant extracts, used
in Nigerian folk medicine, to identify plants with cytotoxic
activity against five human cancer cell lines.
Methods
Collection of plant material and preparation of extracts
Plant materials (the list of plants studied is given in
Table 1) were obtained by Mr A. A Adejumo at different
Table 1 List of plants screened in this study and their report local uses
Species Family Voucher specimen
(Part used)




Acanthacease TVN-A08 (l,r,s) Syphilis, emetic, urethral discharge,
purgative [17]
4.05
Allanblackia floribunda Oliv. Guttiferae TVN-A33 (l,b,r,f) Malaria, dysentery [18] 4.63
Amaranthus spinosus L. Amaranthaceae TVN-A04 (l,st) Diarrhea, dysentery, Gonorrhea [18] 6.76
Bidens pilosa L. Compositae TVN-A75 (l,b,st) Antidiabetic, anaesthetic [19] 8.64
Bryophyllum pinnatum Lam. Crassulaceae TVN-A64 (l) Respiratory tract infections, antibacterial [20] 1.54
Byrsocarpus coccineus Schumach Connaraceae TVN-A14 (b,l) Jaundice, pile, gonorrhea, venereal disease,
impotence [21]
5.79
Cajanus cajan L. Leguminosae TVN-A09 (l) Smallpox, chicken pox, malaria [18,22] 4.08
Capsicum frutescens L. Solanaceae TVN-A03 (f,s) Malaria, Fever, dysentery [18] 1.94
Chromolaena odorata (L.)
R.M. King & H. Rob.
Rosaceae TVN-A02 (l,st,r) Malaria, antimicrobial [18,23] 9.19
Crassocephalum crepidioides
(Benth.) S. Moore.
Compositae TVN-A34 (l,r,s,f) Indigestion, stomach ache, headache [24] 6.38




(Guill. & Perr.) Brenan
Leguminosae TVN-A65 (b) Poison, cardiac problems, venom intoxication,
inflammatory diseases [22]
12.47
Hoslundia opposita Vahl. Labiatae TVN-A72 (l) Abdominal pains, epilepsy, neurotic
disorders [26]
5.82
Jatropa curcas L. Euphorbiaceae TVN-A19 (l) Ringworm, eczema, ulcer [18] 1.31
Landolphia dulcis Var. Barteri
Apocynaceae
TVN-A07 (b) Rheumatism, cough, kidney diseases,
antibacterial [27]
5.75
Lannea nigritana (Sc. Elliot) Keay. Anacardaceae TVN-A61 (l,b,r) None 5.09
Ocimum basilicum L. Lamiaceae TVN-A10 (l) Gonorrhea, catarrhal conditions, cough,
anthelmintics [28]
9.7
Parkia biglobosa (Jacq.) G. Don.
Leguminosae
TVN-A01 (l) Malaria, fever [18,23] 3.87
Parkia filicoidea Welw. Mimosaceae TVN-A35 (l,st) None 7.02
Pterocarpus santalinoides DC. Fabaceae TVN-A06 (l,st) Insecticidal, larvicidal [17,29,30] 3. 34
Rauvolfia vomitoria Afzel. Apocynaceae TVN-A28 (b) Sedative/mental disorder, antidiabetic,
malaria [19,23]
6.61
Sida acuta Burm. F. Malvaceae TVN-A77 (l,st) Malaria, ulcer, fever [18] 2.47
Tetrapleura tetraptera Taub. Leguminosae TVN-A73 (l,r,s,f) Sickle cell [31] 10.52
Vitex doniana Sw. Verbenaceae TVN-A16 (b,r) Gastroenteritis, diarrhea, antimicrobial [32] 26.75
Plant parts are denoted as follows: 1=leaves, b= Bark st= Stem, s= Seeds, r= Roots.
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times of the year. Specimens were collected from the
western part of Nigeria (Lagos, Ogun, Oyo and Osun
states) from traditional healers and indigenous herbal
merchants. Collected specimens were authenticated by
comparison with corresponding herbarium specimens.
Some samples have been deposited at the Department of
Biological Science, Tennessee State University, Nashville,
Tennessee, USA.
Plant materials were air dried and separate extracts
were made from the leaves, seeds, stems and bark por-
tions, respectively. The methanolic extracts were pre-
pared by immersing portions of the whole plant (200 g)
in 500–1000 ml of methanol at room temperature
(25°C) and stirred for 6 days. The crude extracts were
filtered and the filtrate evaporated using a rotary evapor-
ator. The dissolved constituents were further dried
under pressurized vacuum conditions. Stock solutions
were prepared by dissolving the dried residue in di-
methyl sulphoxide (DMSO). Extract solutions were
stored at −20°C until use.
Cell lines
The six selected cancer cell lines used in this research
were derived from human breast adenocarcinoma MCF-
7 (ATCC No. HTB-22), BT-20 (ATCC No. HTB-19),
BT-549 (ATCC No. HTB-122), prostate adenocarcinoma
PC-3 (ATCC No. CRL-1435), acute T cell leukemia
Jurkat (ATCC No. TIB-152), and colon adenocarcinoma
SW-480 (ATCC No. CCL-228) cells were provided by
American Type Culture Collection (Rockville, MD).
These cells were grown in RPMI-1640, with the excep-
tion of MCF-7, which was grown in Dulbecco’s modified
eagle medium (DMEM); all supplemented with 10% heat
inactivated fetal bovine serum (FBS), 2 mM L-glutamine,
and 1% penicillin-streptomycin. DMEM was also supple-
mented with 0.01 mg/ml insulin and 1mM sodium
pyruvate. Cells were incubated in a 5% CO2 humidified
incubator at 37°C and passaged bi-weekly.
Trypan blue exclusion viability assay
Anticancer activity was determined using this assay to
measure cell viability [28]. MCF-7, BT-20, BT-549, PC-3,
JURKAT and SW-480 cell lines were plated at densities
of 1 × 105 and 5 × 104 per well in 12-well and 24-well
tissue culture plates, respectively. Cells were incubated
at 37°C and 5% CO2 for 24 h, after which the cells re-
ceived treatment with fresh medium supplemented with
extracts at concentrations ranging between 0.01 μg/ml-
200 μg/ml, for a total volume of 1 ml-2 ml per well in
24 and 12-well plate formats, respectively. The negative
controls received fresh medium supplemented with the
experimental vehicle, DMSO only. Following 72 h of in-
cubation at 37°C, the cells were trypsinized with 0.25%
trypsin-EDTA solution. Cells were then resuspended in
phosphate buffer saline (PBS) and stained with 0.4% Try-
pan blue dye solution (v/v in PBS). Live cells are ex-
cluded from the stain while dead cells absorb the stain
appearing blue in color under a light microscope enab-
ling the enumeration of viable cells. Cell counts were
expressed as mean ± standard deviation (SD), represen-
tative of three separate experiments.
AlamarBlue™ Metabolic assay
This assay incorporates a fluorometric/colorimetric
growth indicator based on detection of metabolic activity
in which living cells yield a very strong fluorescent prod-
uct [33]. MCF-7, BT-20, BT-549, PC-3, Jurkat, and SW-
480 cell lines were plated at 1 × 104 cells per well in a
96-well black plate and stabilized in medium at 37°C
and 5% CO2 for 24 h. Following the first 24 h, cells re-
ceived fresh medium supplemented with test extracts at
final concentrations ranging between 0.01 μg/ml-200 μg/
ml, in a total volume of 200 μl per well. The negative con-
trol received the experimental vehicle DMSO at the same
end-concentration of 0.1%. Cytotoxicity as indicated by a
reduction in cellular metabolic activity was assayed at 72
h, using AlamarBlue™ (Invitrogen); 20 μl of alamar blue
dye (end-concentration of 10%) was added to each well
and the plates incubated at 37°C overnight. The plates
were then analyzed for fluorescence (F) using the
SpectraMax Gemini EM microtiter plate reader at dual
wavelengths (560 nm λ excitation, 590 λ nm emission).
SoftMax Pro 4.7.1 was used to analyze the data. The fol-
lowing formula was used to calculate the inhibition of cell
growth: inhibition (%) = (1 – mean F value of treatment
group/mean F value of control) × 100.
Statistical analysis
Quantitative values obtained per treatment were converted
to percentage inhibition. Regression analysis was used to
compute the inhibition concentration required to produce
a 50% reduction in cell viability (IC50). Results were
expressed as the mean ± SD of values obtained in triplicate
from three independent experiments. Statistical differences
between correlated samples were evaluated using Student's
t-test and noted to be significantly different where p < 0.05.
Composite treatments were compared using one-way ana-
lysis of variances (ANOVA) and considered significantly
different where probability values were found to be equal
to or less than 0.05.
Results and discussion
Samples collected in this study were selected to include
plants that have suggested bioactivity on the basis of
their non-reported traditional usage as medicines. The
following selected plants have been reported to be used
in traditional treatments for various diseases and ail-
ments ranging from headache, fever, throat and neck
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ailments, tonsillitis, cough, bronchitis, asthma, tubercu-
losis, pneumonia, constipation, hernia, dysentery, diar-
rhea; diseases due to infections from intestinal worm,
filarial; venereal diseases such as gonorrhea, syphilis; dis-
eases of the skin like leprosy, ulcers, sores, boils and other
bacterial infections; also systemic diseases, malaria, yellow
fever, measles, and small pox; as well as epilepsy, cardio-
vascular disease, diabetes, high blood pressure, inflamma-
tory conditions and other diseases of liver, kidney, muscle
and bone. This resulted in a set of 24 crude methanolic
extracts from collected plants shown in Table 1.
The major aim of this study was to identify potential
anticancer extracts that were effective, not by virtue of
high concentration alone, rather by specific activity dem-
onstrated even at low doses. In order to achieve this
aim, the maximum test concentration was set at 200 μg/
ml, as the criteria for identifying plants with potent ac-
tivity within range. Using this criterion, plants with less
than 50% inhibitory activity within the test range were
excluded from further screening. Although such plants
may likely demonstrate greater cytotoxicity at higher
concentrations, the focus in this study was limited to
plant extracts that caused substantial growth inhibition
in a given cell line within the test concentration range of
< 200 μg/ml. The assumption was that such activity elic-
ited in the plants’ crude state would be indicative of even
greater potent effects in the purified state. As a prelimin-
ary means of initially identifying extracts with activity,
the effects of treatment were evaluated in vitro, in a two
dose assay testing lower and upper concentrations of 20
and 200 μg/ml against human carcinoma cell lines. All
cytotoxic activity was assessed at 72 h following
Table 2 Percent inhibiton values of plants crude extracts on three human cancer cell lines at 20 and 200 μg/ml
concentrations
Species T-549 BT-20 PC-3
20 μg/ml 200 μg/ml 20 μg/ml 200 μg/ml 20 μg/ml 200 μg/ml
Acanthus montanus 7 ± 5.01 10 ± 3.45 Nd 27 ± 8.38* Nd <5
Allanblackia floribunda 66 ± 6.51* 96 ± 3.48* 21 ± 4.55 80 ± 5.38* 13 ± 0.58 92 ± 5.29*
Amaranthus spinosus 16 ± 3.86 <5 8 ± 1.72 32 ± 8.14 Nd Nd
Bidens pilosa 23 ± 9.50 97 ± 1.63* Nd 93 ± 1.73* 35 ± 1.08 95 ± 1.53
Bryophyllum pinnatum 24 ± 6.08 96 ± 1.68* Nd 81 ± 6.51* Nd 95 ± 1.62*
Byrsocarpus coccineus Bark 20 ± 2.51 100 Nd 93 ± 2.66* Nd 97 ± 6.15*
Leaves 54 ± 1.76 100 Nd 100 Nd 100
Cajanus cajan 9 ± 1.46 99 ± 0.58* <5 99 ± 0.17* 23 ± 1.53 100
Capsicum frutescens <5 10 ± 0.96 <5 39 ± 3.96 11 ± 2.40 41 ± 1.08
Chromolaena odorata 13 ± 4.21 8 ± 3.06 6 ± 0.81 39 ± 2.12 Nd Nd
Crassocephalum crepidioides 14 ± 2.14 51 ± 1.04* Nd 10 ± 5.21 Nd 9 ± 1.01
Daniellia oliveri 35 ± 1.55 97 ± 0.21* <5 66 ± 4.16* 22 ± 10.50 47 ± 5.78
Erythrophleum suaveolens 100 100 100 100 100 100
Hoslundia opposita 19 ± 0.55 96 ± 0.42* Nd 93 ± 1.67* Nd 51 ± 8.21*
Jatropa curcas 45 ± 4.01 100 29 ± 0.61 87 ± 1.52* Nd Nd
Landolphia dulcis 83 ±1.39 100 Nd 11 ± 1.21 Nd 9 ± 3.11
Lannea nigritana 32 ± 0.32 90 ± 0.17* Nd Nd Nd 21 ± 7.71*
Ocimum basilicum <5 <5 <5 <5 <5 Nd
Parkia biglobosa <5 75 ± 3.36* 7 ± 5.13 72 ± 0.61 17 ± 7.21 93 ± 6.03*
Parkia filicoidea <5 67 ± 3.06* <5 27 ± 3.70 10 ± 0.70 76 ± 1.53*
Pterocarpus santalinoides 17 ± 2.52 98 ± 0.45* <5 11 ± 5.03 <5 17 ± 0.40
Rauvolfia vomitoria <5 37 ± 1.12 19 ± 0.72 33 ± 1.71 <5 8 ± 4.23
Sida acuta 91 ± 5.86* 95 ± 3.16* 25 ± 5.03 97 ± 0.57* 27 ± 2.20 97 ± 1.80*
Tetrapleura tetraptera 66 ± 1.38* 100 58 ± 9.13* 100 Nd Nd
Vitex doniana Bark <5 89 ± 1.27* Nd 55 ± 1.33 Nd <5
Root 21 ± 1.46 56 ± 2.35* Nd 61 ± 1.06 Nd 57 ± 1.25
The antiproliferative/cytotoxic effect is expressed in terms of the percent inhibition of cells growth relative to the DMSO control after 72 h exposure to the
extracts. Results are expressed as mean ± SD of three rreplicate experiments. Nd = Not determined. *There was a significant difference in cell inhibition in
extract-treated cultures compared with DMSO-control in all cell lines (P<0.05).
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treatment. The Trypan blue exclusion method and the
AlamarBlue™ metabolic assay were utilized to quantify
cytotoxic or cytostatic effects.
Overall cytoxicity varied between extracts and between
cell lines. Table 2 shows the percent inhibition of treated
cells relative to the untreated controls. Initially, plants
were screened individually against one or more cancer
types from the panel of cell lines consisting of BT-549
(breast carcinoma), BT-20 (breast carcinoma) and PC-3
(prostate carcinoma). Then leads for secondary screen-
ing were selected on the basis of inhibition ≥ 50% at
concentrations below the set upper limit tested. Plants
that were considered moderately active showed cytoxi-
city ≥ 80% inhibition at 200 μg/ml, however some of
these plants were weakly cytotoxic at 20 μg/ml. Very ac-
tive extracts showed 50% or greater inhibition at 20 μg/
ml, these plants were selected for further screening at a
wider range of concentrations. Extracts exhibiting ≥ 80%
inhibition at 20 μg/ml were considered potent and iden-
tified as prime targets for further screening.
Based on these criteria, 12 of these plants were catego-
rized as moderately active. There were 6 plants that were
considered very active to potent at least against one
cancer cell line, these included Byrsocarpus coccineus
with 54% inhibition at 20 μg/ml (against BT-549),
Allanblackia floribunda and Tetrapleura tetraptera
which both exhibited the lowest inhibition of 66% at 20
μg/ml in this category (against BT-549). Landolphia
dulcis and Sida acuta showed between 83% - 91% at 20
μg/ml (against BT-549) and the most potent was
Erythrophleum suaveolens, exihibiting 100% inhibition at
20 μg/ml. In terms of potency between cell lines,
Erythrophleum suaveolens showed the most consistent
activity, causing total growth inhibition of all three cell
lines, BT-549, BT-20 and PC-3. The latter were analyzed
comprehensively in the second phase of screening.
Amongst the plants that were moderately active, there is
a trend of selectivity towards BT-549. Allanblackia flori-
bunda showed significant variation at 20 μg/ml,
inhibiting BT-549 by 66%, but only 21% and 13% of
BT-20 and PC-3 respectively. Similarly, amongst the very
active plants, Sida acuta caused 91% inhibition of BT-
549 viability at 20 μg/ml, however the same concentra-
tion resulted in only 25% and 27% inhibition of BT-20
and PC-3, respectively.
In Table 3, regression analysis was done to compute
the inhibition concentration required to produce a 50%
reduction in cell viability (IC50) of the plant extracts
(R2 ≥0.9). The concentration that causes 50% inhibition
of the cancer cells by the crude extract of the Nigerian
plants species investigated are displayed in Table 3. The
solvent extracts of 4 plants showed moderate IC50 value
ranging from 62.5-177.3 μg/ml (Table 3) against different
cancer cell lines. Among them is the bark of Vitex
Table 3 IC50 (μg/mL) values for the in vitro cytotoxic activity of plants crude extracts on five human cancer cell lines
Species BT-549 BT-20 PC-3 SW-480 JURKAT
Allanblackia floribunda 14.7 ± 0.23 48.3 ± 2.90 29.4 ± 0.69 57.1 ± 1.16 Nd
Bidens pilosa 43.1 ± 6.09 53.7 ± 2.16* 47.7 ± 2.69* Nd 75.6 ± 1.06*
Bryophyllum pinnatum 48.2 ± 1.56 82.4 ± 0.17* 48.3 ± 1.05* Nd Nd
Byrsocarpus coccineus Bark 24.6 ± 0.99 52.9 ± 4.11* 43.7 ± 1.02* Nd 65.2 ± 0.87*
Leaves 18.6 ± 4.85 31.3 ± 0.53* 29.1 ± 0.64* Nd 43.4 ± 1.77*
Cajanus cajan 56.1 ± 10.09 56.8 ± 2.60 50.5 ± 0.76 52 ± 0.53 Nd
Daniellia oliveri 28.1 ± 0.56 153.1 ± 1.56 130.0 ± 0.45 147.0 ± 0.47 Nd
Erythrophleum suaveolens 0.55 ± 0.18 0.50 ± 0.03 1.30 ± 0.14 0.80 ± 0.11 0.20 ± 0.05
Hoslundia opposita 76.4 ± 7.89 56.1 ± 1.57 59.7 ± 8.11 Nd >200
Jatropa curcas L. 21.3 ± 0.38 33.4 ± 0.70 >200 >200 >200
Landolphia dulcis 16.3 ± 4.31 >200 >200 >200 Nd
Lannea nigritana 48.2 ± 3.52 Nd >200 Nd 53.5 ± 0.35*
Parkia biglobosa 100.0 ± 0.67 125.0 ± 2.21 56.1 ± 0.45 136.0 ± 0.81 Nd
Parkia filicoidea 149.0 ± 2.65 >200 94.3 ± 0.50 Nd Nd
Pterocarpus santalinoides 57.9 ± 0.35 >200 >200 >200 10.2 ± 0.25
Sida acuta 10.3 ± 0.21 41.1 ± 1.05 37.1 ± 0.18 Nd 42.3 ± 0.79
Tetrapleura tetraptera 9.1 ± 1.40 23.1 ± 7.05 Nd Nd 37.5 ± 5.13*
Vitex doniana Bark 62.5 ± 0.23 171.1 ± 1.33 >200 89.2 ± 6.65 84.0 ± 1.13
Root 44.9 ± 0.10 152.3 ± 1.22 177.3 ± 1.01 45.6 ± 1.35 43.4 ± 0.64
Results are expressed as mean ± SD (μg/mL) of three replicate experiments. Nd = Not determined. There was a significant difference in cell inhibition in
extract-treated cultures compared with DMSO-control in all cell lines (P<0.05).
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doniana with IC50 value of 62.5, 84, 89.2 and 171.1 μg/
ml (against BT-549, JURKAT, SW-480 and BT-20 re-
spectively) and the root of the same plant showed IC50
value of 152.3 and 177.3 μg/ml against BT-20 and PC-3.
Hoslundia opposita also showed significant activity
against BT-549, with an IC50 value of 76.4 μg/ml and the
bark of Byrsocarpus coccineus showed similar activity
against JURKAT with IC50 value of 65.2 μg/ml (Table 3).
Other cytotoxic activity in the IC50 value range from
94.3-153.1 μg/ml against different cancer cell lines were
also observed, these include Parkia biglobosa (IC50 value:
125 μg/ml against BT-20 and 136 μg/ml against SW-480),
Daniellia oliveri (IC50 value: 153.1 μg/ml against
BT-20, 130 μg/ml against PC-3 and 147 μg/ml against
SW-480) and Parkia filicoidea (IC50 value: 94.3 μg/ml
against PC-3 and 149 μg/ml against BT-549).
Cajanus cajan exhibited similar cytotoxic activity
against all types of cancer cell lines used, showing IC50
value between 50.5-56.1 μg/ml, while the extracts of
Allanblackia floribunda (IC50 = 48.3 μg/ml against
BT-20 and IC50 = 57.1 μg/ml against SW-480), Parkia
biglobosa (IC50 = 56.1 μg/ml against BT-20), Pterocarpus
santalinoides (IC50 = 57.9 μg/ml against BT-549) and
the bark of Byrsocarpus coccineus (IC50 = 43.7 μg/ml
against PC-3 and IC50 = 52.9 μg/ml against BT-20) all
presented moderate cytotoxic activity. Sida acuta
exhibited moderate cytotoxic activity against BT-20,
JURKAT and PC-3 (IC50 = 41.1, 42.3 and 37.1 μg/ml re-
spectively), while the extract of the root of Vitex
doniana exhibited similar cytotoxic activity against
BT-20, SW-480 and JURKAT (IC50 = 44.9, 45.6 and 43.4
μg/ml respectively). Other plant extracts that showed
moderate cytotoxic activity include Bidens pilosa (IC50 =
43.1 μg/ml against BT-549, IC50 = 53.7 μg/ml against
BT-20 and IC50 = 47.7 μg/ml against PC-3), Lannea
nigritana (IC50 = 48.2 μg/ml against BT-549 and IC50 =
53.5 μg/ml against JURKAT) Bryophyllum pinnatum
(IC50 = 48.2 μg/ml against BT-549 and 48.3 μg/ml
against JURKAT) and Tetrapleura tetraptera (IC50 =
37.5 μg/ml against JURKAT).
The criteria of cytotoxicity activity for the crude ex-
tracts, as established by the American National Cancer
Institute NCI) is an IC50 < 30 μg/ml in the preliminary
assay [34]. Interestingly, about nine extracts showed
Figure 1 Time and dose response of Erythrophleum suaveolens at 0.5 μg/ml and 1 μg/ml on cell proliferation of MCF-7 and BT-549
breast cancer cell lines. Cells were plated at 10^4 cells per well in a 96-well plates and treated for 24, 48 and 72 hr. Values are presented as
means (n = 3) ± S.D. *Statistical difference (p < 0.05).
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similar IC50 value close to this concentration. The ex-
tract of the leaves of Jatropha curcas exhibited cytotoxic
activity against human breast adenocarcinoma cells
(BT-549) with IC50 value of 21.3 μg/ml. Similar cytotoxic
activity has been previously reported, where the root of
Jatropha curcas inhibits the proliferation of human
colon adenocarcinoma cells (HT-29, IC50 = 18.3 μg/ml)
and human hepatocytes cells (Chang liver, IC50 = 33.3
μg/ml) [35]. The extract of the leaves of Byrsocarpus
coccineus also exhibited good cytotoxic activity against
human breast adenocarcinoma cell lines BT-549, BT-20
and prostate adenocarcinoma cell line PC-3 (IC50 = 18.6,
31.3 and 29.1 μg/ml respectively), while the bark of the
same plant showed IC50 value of 24.6 μg/ml against BT-
549 (Table 3). Daniellia oliveri, Allanblackia floribunda,
Sida acuta and Tetrapleura tetraptera also exhibited
promising in vitro cytotoxic activity against BT-549
(IC50 = 28.1, 14.7, 10.3 and 9.1 μg/ml respectively). It is
noteworthy to mention that a weak antitumor activity of
Allanblackia floribunda has been reported using a po-
tato disc tumor induction assay (13.9% inhibition at 100
μg/disc) [36], while Pieme and coworkers also reported
that Sida acuta inhibits the proliferation of human
hepatoma cells (HepG-2) by 51.62% at 250 μg/ml [37].
Among plants extracts screened on multiple cell lines,
four species showed a degree of selectivity. Jatropha
curcas showed selective activity on breast cancer cell line
(IC50 = 21.3 μg/ml against BT-549 and IC50 = 33.4 μg/
ml against BT-20), but no activity was noticed against
other types of cancer cell line (PC-3, SW-480, JURKAT).
Similar selectivity for BT-549 and T-cell leukemia cell line
(JURKAT) was also noticed for Daniellia oliveri (IC50=
28.1 and 15 μg/ml). Sida acuta showed somewhat selectiv-
ity against BT-549, with IC50 value of 10.3 μg/ml, while a
pronounced selective activity was noticed for Pterocarpus
santalinoides against JURKAT (IC50 = 10.2 μg/ml).
The extract from the bark of Erythrophleum suaveolens
exhibited the most potent activity against all types of can-
cer cell line used (IC50 = 0.2-1.3 μg/ml, Table 3) including
breast cancer cells MCF-7 (IC50 = 0.63 μg/ml). Earlier
studies by Sowemimo and co-workers revealed that
the ethanolic extract of Erythrophleum suaveolens leaves
showed toxicity and mutagenic activity using brine shrimp
lethality test [38].
In order to gain more insight on the mechanism of
Erythrophleum suaveolens cytoxicity, it was necessary to
evaluate whether the induced anticancer activity was a
factor of dosage alone or dosage in correlation with time
of exposure (Figure 1).
At low concentrations of Erythrophleum suaveolens a
decrease of MCF-7 viability to 30% was detected after 48
h of exposure. As shown in Figure 1, with treatment of
MCF-7, cytotoxic effects are contingent upon exposure
time, which is seen by the drastic increase from 30% in-
hibition at 24 h to 80% inhibition after 72 h. However, in
BT-549 toxicity is dose dependent. No antiprolifera-
Figure 2 Microscopic images of Erythrophleum suaveolens-treated and untreated cells. (A) DMSO treated BT549 cells after 24 h (top left
panel) (B) Detachment from culture plate (BT549) after 24 h exposure to Erythrophleum suaveolens at its IC50 value (0.55 μg/ml), (top right panel)
(C) DMSO treated BT549 cells after 48 h (bottom left panel) (D) Cytostatic effects after 48 h exposure to Erythrophleum suaveolens at its IC50 value
(0.55 μg/ml), (right panel). All images are magnified at 40×. Images shown are representative of at least five such fields of view per sample and
three replicates.
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tion effect of Erythrophleum suaveolens is detected
within 48 h of exposure to a concentration of 0.5 μg/ml,
where in fact greater cell number is observed in treated
cells. With increase in dose, at 1 μg/ml, exposure to
Erythrophleum suaveolens for 24 h is associated with a
dramatic fall in BT-549 viability of 80%.
This loss of viability increases only about 10% by 72 h
indicating that the effects of Erythrophleum suaveolens
on BT-549 are fairly rapid within a 24 h period. The data
obtained in these preliminary studies provide enough
evidence to suggest that Erythrophleum suaveolens does
in fact contain potent cytotoxic compounds that inhibit
tumor cells in vitro. In the crude form these active com-
pound(s) may elicit synergistic effects or may even be
subdued by the presence of other inactive components.
The time response curves reveal a peak in inhibitory
activity after 18 h of exposure indicating that within that
time frame, enough cellular damage has been inflicted to
inhibit approximately 60-80% of cell viability. Physiolo-
gically, cells become detached from the base of the cul-
ture plate suggesting an interruption of the extracellular
matrix and inhibition of cell to cell contact (Figure 2).
Analysis with AlamarBlue indicates a complete shut-
down of metabolic activity. Furthermore, microscopic
comparisons between cells treated with Erythrophleum
suaveolens and non-treated controls suggest cytostatic
effects due the presence of active cellular expansion in
controls, which is inhibited in the treated.
Conclusions
In this study 24 indigenous plants from Southwestern
Nigeria were screened for their ability to induce cytotox-
icity human cancer cell lines, the results of the study
have therefore demonstrated that reliance on ethnome-
dicinal information as a strategic approach in the selec-
tion of native plants is an effective method that yields
positive selection of taxonomically diverse leads with
very few unfavorable candidates.
In conclusion, this study has demonstrated the suc-
cessful streamlining of the screening process of bioactive
plants with anticancer activity, by eliminating poor can-
didates on the basis of cytotoxic criterion that takes into
consideration effective dosage. Results obtained from
folk medicinal plants screened indicate that 18 plant ex-
tracts exhibited promising cytotoxic activity against hu-
man carcinoma cell lines. Erythrophleum suaveolens was
found to demonstrate potent anti-cancer activity in this
study exhibiting IC50 = 0.2-1.3 μg/ml. Among the active
extracts, the species with the highest hit rate of demon-
strated anticancer activity in this study were from the
phylum Leguminosae, which is a large and economically
important family of flowering plants which is commonly
known as the legume family, pea family, bean family or
pulse family. Extensive further analysis on the anticancer
properties of Erythrophleum suaveolens compared with
those of an anticancer drug compound as the positive
control is currently underway. Efficacy and mechanisms
of action in various normal and cancer cell models
in vitro, coupled with bio-assay guided purification in
order to elucidate active anticancer compound(s) from
the crude extract will be reported in due course.
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